TScan Therapeutics, Inc. ( TCRX) - Key Metrics
TCRX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.01 | -$0.23 | -$0.21 | -$0.22 |
| 2026Q1 | $0.01 | -$0.22 | -$0.19 | -$0.19 |
| 2025Q4 | $0.02 | -$0.18 | -$0.25 | -$0.25 |
| 2025Q3 | $0.02 | -$0.28 | -$0.25 | -$0.26 |
| 2025Q2 | $0.02 | -$0.28 | -$0.26 | -$0.27 |
TCRX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -1.07 |
| 2026Q1 | 0% | -1.15 |
| 2025Q4 | 0% | -1.39 |
| 2025Q3 | 0% | -1.63 |
| 2025Q2 | 0% | -1.29 |
TCRX
Price: $0.75
52 week price:
Earnings Per Share: -0.90 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 133500
Market Capitalization: 52.8 million